Get fast and accurate PCR results, virtually anywhere.

Cepheid’s menu of more than 20 FDA-cleared and emergency-use authorized tests run on the GeneXpert® family of systems to provide accurate, high-quality real-time PCR results when and where you need them most.


Improved outcomes* with PCRplus testing

Cepheid's tests enable improved clinical outcomes, operational efficiencies, and patient experience across the continuum of care. That's the PCRplus advantage.









Healthcare-Associated Infections


C. difficile


69-85% decrease
in infection rate1





33% decrease
in isolation days2


$2.4M savings

on cost of care3

Respiratory Infections


Strep A


18% increase
in accurate test results reduced empiric treatment3





387-day decrease
in unnecessary droplet precautions4





$400K savings
in bed costs and Tamiflu® usage4



Women's & Sexual Health




12.5% increase
in appropriate initial treatment5





2 hours per day reduction
in staff time spent on phone calls with anxious patients6





$37K savings
in additional testing, antimicrobial utilization, and ED readmission5


GeneXpert systems and GeneXpert Infinity systems can run our full menu of moderate complexity tests for respiratory diseases, women's and sexual health, healthcare-associated infections, and oncology. GeneXpert Xpress systems can run our CLIA waived menu of respiratory tests. Women's and sexual health tests are coming soon — designed for CLIA waived testing.

“The GeneXpert Xpress is a game changer and will save many lives, and I can't thank you enough for giving us a chance to make a difference in the lives of our patients and local economy.”
Dr. Hall, Crewe Medical Center, Crewe, VA

A test can change a life. That's why we're committed to a higher level of PCR exellence. One that combines speed, accuracy, and flexibility to deliver unmatched results.

Speed, plus
Accuracy, plus

That's the PCRplus advantage.
From Cepheid.



With more than 20 FDA-cleared or authorized tests (including moderate complexity and CLIA waived tests), Cepheid is the ideal real-time PCR diagnostic partner for improved clinical decision-making and optimized patient care.

Visit our Education Center for more educational webinars, websites, and videos.

Visit Now



The PCRplus advantage delivers a higher level of PCR excellence by bringing together:

  • Accurate results that clinicians and patients can rely on.

  • Speed and efficiency to deliver on-demand answers WHEN they are needed most.

  • A flexible delivery platform - like the GeneXpert® system and Xpert® test cartridges that can deliver those results WHERE they are needed, from the lab to the point of care.

  • Quality of test design - a proven track record of delivering quality across a broad menu of test products. Experience matters.

  • Simplicity - a solution that is easy to learn, adopt, and operate across a variety of settings and users.

GeneXpert Systems are available in a two, four, 16, 48, or 80-module configuration. In addition, our CLIA-Waived GeneXpert Xpress is available for front line access and control, anywhere you need it. All GeneXpert Systems have our proven GeneXpert module at their analytic heart, and use the same patented cartridge technology for every Xpert test.

Cepheid's GeneXpert Xpress is an efficient, streamlined, and scalable workflow solution that delivers CLIA waived molecular results. The GeneXpert Xpress system produces quality results without any specialized training or daily or weekly maintenance. It’s a true walk-away system with short sample prep time that will provide faster results before your patients even leave your facility.


1. Cepheid. Ephraim McDowell Regional Medical Center improves adherence to optimized testing protocols for Clostridium difficile resulting in lower C. difficile rates and decreased patient time in isolation. (0664-03) [Impact Brief]
2. Cepheid. Leading-edge molecular testing drives improved process and enhanced patient care. (0566-01) [Impact Brief]
3. Cepheid. Millard Henry Clinic (MHC) improves treatment accuracy through the use of Xpert® Xpress Flu/RSV and antimicrobial stewardship while maintaining efficient patient flow during a very busy flu season. (0716-01) [Impact Brief]
4. Cepheid. Einstein Medical Center Montgomery sees significant reduction in oseltamivir (Tamiflu®) usage and improved length of stay through the use of real-time PCR testing with Xpert® Flu/RSV XC. (0724-02.A) [Impact Brief]
5. Cepheid. Mercy Health Saint Mary’s in Grand Rapids, MI reduces time to result and improves treatment accuracy through the use of Xpert® CT/NG and antimicrobial stewardship (0629-01) [Impact Brief]
6. Cepheid. Women’s Health Group reduces time to result and improves treatment accuracy through the use of Xpert® CT/NG and antimicrobial stewardship (0700-01) [Impact Brief] Studies/ Cepheid_The_Womens_Health_Group_Case_Study_US_0700_01.pdf

* Projections and realized results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
^CLIA waived tests available for use on the GeneXpert Xpress system.
# With early assay termination (EAT) for positive results. Full tests runtimes are as follows: Xpert Xpress Flu is 30 minutes, Xpert Xpress CoV-2 plus is approximately 30 minutes, Xpert Xpress Strep A is 24 minutes, Xpert TV is 70 minutes, Xpert C. difficile is 43 minutes.
†For positive Flu only or RSV only. Reporting negatives and combined reporting in 30 minutes.
‡ These tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2 plus has been authorized only for the detection of nucleic acids from SARS-CoV-2, and not for any other viruses or pathogens. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**With early assay termination for positives when running SARS-CoV-2 only. Full run time is 36 min.
^^Research Use Only (RUO). Not for use in diagnostic procedures.

Request Information

* Required Field


In submitting this form, you agree to be contacted by Cepheid to receive information on products, goods, and services, which may include similar products, goods, or services from our affiliates. Consent may be withdrawn at any time. For additional information about how we handle your personal data, please review our online privacy policy.